Intel stock spikes after report of possible US government stake
The transaction was executed to cover tax withholding obligations related to the vesting of restricted stock units, as noted in the filing. Following this sale, Waltermire retains ownership of 4,955 shares of Madrigal Pharmaceuticals (NASDAQ:MDGL). The company maintains a healthy financial position with a current ratio of 5.98, indicating strong liquidity. The sale was automatic and not at the discretion of the executive, as specified in the company's footnotes accompanying the filing. Investors can access comprehensive analysis and 12 additional ProTips for MDGL through InvestingPro's detailed research reports.
The transaction was executed to cover tax withholding obligations related to the vesting of restricted stock units, as noted in the filing. Following this sale, Waltermire retains ownership of 4,955 shares of Madrigal Pharmaceuticals. The company maintains a healthy financial position with a current ratio of 5.98, indicating strong liquidity. The sale was automatic and not at the discretion of the executive, as specified in the company's footnotes accompanying the filing. Investors can access comprehensive analysis and 12 additional ProTips for MDGL through InvestingPro's detailed research reports.
In other recent news, Madrigal Pharmaceuticals reported robust preliminary financial performance, with fourth-quarter sales ranging between $100 million to $103 million and full-year 2024 sales between $177 million to $180 million. These figures surpassed the Goldman Sachs and FactSet consensus estimates. Madrigal's strong sales results are attributed to sustained patient demand and comprehensive physician prescribing for its drug, Rezdiffra.
Evercore ISI, Oppenheimer, TD Cowen, and Piper Sandler have all maintained their positive ratings on Madrigal. Evercore ISI raised the price target to $392 from $360, while Oppenheimer increased the price target to $400. TD Cowen reaffirmed their price target of $390, and Piper Sandler maintained an Overweight rating.
Madrigal is also actively pursuing expansion efforts, with the anticipated approval and launch of Rezdiffra in Europe by mid-2025. The company has completed patient enrollment for the MAESTRO-NASH OUTCOMES trial, which evaluates resmetirom as a potential treatment for NASH cirrhosis. These are the recent developments in Madrigal's ongoing efforts to improve treatment options for NASH patients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.